Weight-Loss Drugs Should be Covered, New Poll Finds
By Physician’s Briefing Staff HealthDay Reporter
WEDNESDAY, Dec. 13, 2023 -- According to the latest University of Michigan National Poll on Healthy Aging, about three in four older Americans (76 percent) believe Medicare should cover the cost of weight-loss medications like Ozempic, Wegovy, or Zepbound.
More than four out of five older adults (83 percent) think insurance companies should pay for drugs that help people with obesity manage their weight, according to poll results from more than 2,600 people ages 50 to 80 years.
A 2003 law currently prohibits Medicare from covering medications specifically for weight loss, although the federal insurance program can cover drugs that help people with type 2 diabetes manage their weight, researchers said in background notes.
In the poll, researchers found wide interest among older adults for using weight-loss drugs to drop extra pounds. About one in four poll respondents said they are overweight, and 63 percent of them are interested in taking a weight-loss medication. So are 45 percent of those who have diabetes, regardless of their weight. The drugs appear to make a good impression as well. Among those who had ever taken a weight-loss medication, 83 percent said they would do so again.
Poll results show that Ozempic/Wegovy has largely driven this new interest in weight-loss medications. The poll revealed that 61 percent of older adults had heard of the diabetes drug Ozempic, but only 18 percent had heard of the version approved specifically for weight loss, Wegovy. Other weight-loss drugs were much less familiar to poll respondents. Only 13 percent had heard of an older drug called phentermine, and just 3 percent had heard of Qsymia, Saxenda, or Contrave.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Text Messages + Financial Incentives Boost Weight Loss at 12 Months
WEDNESDAY, May 15, 2024 -- Among men with obesity, an intervention with text messaging plus financial incentive significantly improves weight loss compared with a control group...
GLP-1 Receptor Agonist Use Increases Likelihood of Antidepressant Prescription
WEDNESDAY, May 15, 2024 -- Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a...
Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist
TUESDAY, May 14, 2024 -- One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.